OBJECTIVE: Different HIV-1 antigen specificities appear in sequence after HIV-1 transmission and the immunoglobulin G (IgG) subclass responses to HIV antigens are distinct from each other. The initial predominant IgG subclass response to HIV-1 infection consists of IgG1 and IgG3 antibodies with a noted decline in some IgG3 antibodies during acute HIV-1 infection. Thus, we postulate that multiple antigen-specific IgG3 responses may serve as surrogates for the relative time since HIV-1 acquisition. DESIGN: We determined the magnitude, peak, and half-life of HIV-1 antigen-specific IgG1 and IgG3 antibodies in 41 HIV-1-infected individuals followed longitudinally from acute infection during the first appearance of HIV-1-specific antibodies through approximately 6 months after infection. METHODS: We used quantitative HIV-1-binding antibody multiplex assays and exponential decay models to estimate concentrations of IgG1 and IgG3 antibodies to eight different HIV-1 proteins including gp140 Env, gp120 Env, gp41 Env, p66 reverse transcriptase, p31 Integrase, Tat, Nef, and p55 Gag proteins during acute/recent HIV-1 infection. RESULTS: Among HIV-1-specific IgG3 responses, anti-gp41 IgG3 antibodies were the first to appear. We found that anti-gp41 Env IgG3 and anti-p66 reverse transcriptase IgG3 antibodies, in addition to anti-Gag IgG3 antibodies, each consistently and measurably declined after acute infection, in contrast to the persistent antigen-specific IgG1 responses. CONCLUSION: The detailed measurements of the decline in multiple HIV-specific IgG3 responses simultaneous with persistent IgG1 responses during acute and recent HIV-1 infection could serve as markers for detection of incident HIV infection.
OBJECTIVE: Different HIV-1 antigen specificities appear in sequence after HIV-1 transmission and the immunoglobulin G (IgG) subclass responses to HIV antigens are distinct from each other. The initial predominant IgG subclass response to HIV-1 infection consists of IgG1 and IgG3 antibodies with a noted decline in some IgG3 antibodies during acute HIV-1 infection. Thus, we postulate that multiple antigen-specific IgG3 responses may serve as surrogates for the relative time since HIV-1 acquisition. DESIGN: We determined the magnitude, peak, and half-life of HIV-1 antigen-specific IgG1 and IgG3 antibodies in 41 HIV-1-infected individuals followed longitudinally from acute infection during the first appearance of HIV-1-specific antibodies through approximately 6 months after infection. METHODS: We used quantitative HIV-1-binding antibody multiplex assays and exponential decay models to estimate concentrations of IgG1 and IgG3 antibodies to eight different HIV-1 proteins including gp140 Env, gp120Env, gp41 Env, p66 reverse transcriptase, p31 Integrase, Tat, Nef, and p55Gag proteins during acute/recent HIV-1 infection. RESULTS: Among HIV-1-specific IgG3 responses, anti-gp41 IgG3 antibodies were the first to appear. We found that anti-gp41 EnvIgG3 and anti-p66 reverse transcriptase IgG3 antibodies, in addition to anti-GagIgG3 antibodies, each consistently and measurably declined after acute infection, in contrast to the persistent antigen-specific IgG1 responses. CONCLUSION: The detailed measurements of the decline in multiple HIV-specific IgG3 responses simultaneous with persistent IgG1 responses during acute and recent HIV-1 infection could serve as markers for detection of incident HIV infection.
Authors: Bharat S Parekh; M Susan Kennedy; Trudy Dobbs; Chou-Pong Pau; Robert Byers; Timothy Green; Dale J Hu; Suphak Vanichseni; Nancy L Young; Kachit Choopanya; Timothy D Mastro; J Steven McDougal Journal: AIDS Res Hum Retroviruses Date: 2002-03-01 Impact factor: 2.205
Authors: Kelly A Curtis; M Susan Kennedy; Man Charurat; Abdulsalami Nasidi; Kevin Delaney; Thomas J Spira; S Michele Owen Journal: AIDS Res Hum Retroviruses Date: 2011-06-17 Impact factor: 2.205
Authors: Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: J Khalife; B Guy; M Capron; M P Kieny; J C Ameisen; L Montagnier; J P Lecocq; A Capron Journal: AIDS Res Hum Retroviruses Date: 1988-02 Impact factor: 2.205
Authors: J S McDougal; M S Kennedy; J K Nicholson; T J Spira; H W Jaffe; J E Kaplan; D B Fishbein; P O'Malley; C H Aloisio; C M Black Journal: J Clin Invest Date: 1987-08 Impact factor: 14.808
Authors: Ted Westling; Michal Juraska; Kelly E Seaton; Georgia D Tomaras; Peter B Gilbert; Holly Janes Journal: Stat Methods Med Res Date: 2019-01-09 Impact factor: 3.021
Authors: Karen V Kibler; Benedikt Asbach; Beatriz Perdiguero; Juan García-Arriaza; Nicole L Yates; Robert Parks; Sherry Stanfield-Oakley; Guido Ferrari; David C Montefiori; Georgia D Tomaras; Mario Roederer; Kathryn E Foulds; Donald N Forthal; Michael S Seaman; Steve Self; Raphael Gottardo; Sanjay Phogat; James Tartaglia; Susan Barnett; Anthony D Cristillo; Deborah Weiss; Lindsey Galmin; Song Ding; Jonathan L Heeney; Mariano Esteban; Ralf Wagner; Giuseppe Pantaleo; Bertram L Jacobs Journal: J Virol Date: 2019-01-17 Impact factor: 5.103
Authors: James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts Journal: JCI Insight Date: 2017-04-20
Authors: Eric R Weiss; Galit Alter; Javier Gordon Ogembo; Jennifer L Henderson; Barbara Tabak; Yasin Bakiş; Mohan Somasundaran; Manuel Garber; Liisa Selin; Katherine Luzuriaga Journal: J Virol Date: 2016-12-16 Impact factor: 5.103
Authors: Usha K Sharma; Marco Schito; Alex Welte; Christine Rousseau; Joseph Fitzgibbon; Brandon Keele; Stuart Shapiro; Andrew McMichael; David N Burns Journal: AIDS Res Hum Retroviruses Date: 2012-02-24 Impact factor: 2.205
Authors: Eric P Brown; Anna F Licht; Anne-Sophie Dugast; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman Journal: J Immunol Methods Date: 2012-09-27 Impact factor: 2.303